London · Delayed Price · Currency is GBP · Price in GBX Sareum Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Interim results show stable expenses, a GBP 1.65m loss, and GBP 2.5m cash. 1801 advances toward phase II, 1802 is prepped for licensing, and SRA737 is actively marketed with extended IP. CNS and business development efforts are progressing.
Fiscal Year 2025
-
The meeting reviewed strong progress in clinical and preclinical programs, with SDC-1801 advancing toward phase II and SRA737 reacquired on improved terms. All resolutions passed, while shareholders pressed for better communication and clarity on funding and board share purchases.
-
Pipeline progress continues with a focus on STC-1801, despite a toxicology study setback unrelated to the drug. Operating loss narrowed to under £3 million, with £3.5 million in cash, and partnering remains key for late-stage development.
-
Regained control of SRA737, expanded pipeline, and completed a positive phase I for SDC-1801. Cash position strengthened to over GBP 4 million, with reduced operating expenses and a narrowed loss. Preparing for phase II and exploring licensing and partnership opportunities.
Fiscal Year 2024
-
All AGM resolutions were passed, including director re-elections and share authorities. The board highlighted the completion of a key clinical study, outlined plans for advancing pipeline assets, and addressed questions on strategy, partnerships, and data disclosure.
-
Completed Phase 1 for SDC-1801 with strong safety and PK results, raising £4.4 million to fund Phase 2 preparations. Awaiting milestone updates on SRA737 and advancing SDC-1802 with new funding. Focus remains on risk management, partnering, and regulatory compliance.